InterCure Ltd. regained compliance with Nasdaq's minimum bid price requirement following a delisting notice received on September 1, 2026. The company satisfied the rule by maintaining a closing bid price of $1.00 or greater for ten consecutive business days from August 24 through September 4, 2026. This compliance resolves the delisting proceedings initiated due to the stock trading below $1.00 for 30 consecutive days earlier in 2026. InterCure operates in the cannabis industry as Israel's largest licensed producer of pharmaceutical-grade medical cannabis.
